Beckman-Coulter - is it a good fit ! $60/sh in 1 yr? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Beckman-Coulter - is it a good fit ! $60/sh in 1 yr?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: joarel who wrote (14)	4/1/2000 2:22:00 PM
From: joarel	Read Replies (1) of 16

All, Anyone long on BEC? If they enter the B2B space with other drug, pharmaceutical companies the price should see much higher levels. ~joarel RESEARCH ALERT - Beckman Coulter raised NEW YORK, March 17 (Reuters) - Lehman Bros. on Friday said analyst David Gruber raised his rating of Beckman Coulter Inc. (NYSE: BEC) to buy from outperform. -- said lifted price target to $72 from $60. -- said raised 2000 earnings forecast 3 cents a share to $4.00. -- said sees year 2000 sales growth of 5.6 percent over 1999. -- said sees growth due to launch of prostate cancer screening tool, which will cut back on unnecessary tissue removal and testing from patients. -- said competitor Abbott Laboratories Inc.'s (NYSE: ABT) problems with U.S. government will also partly help Beckman to make competitive inroads and improve sales. -- said company's life sciences division, with 22 percent of firm's sales, is undervalued versus rivals in the high-flying drug development field. -- said company will make inroads in lab automation business. -- said life sciences showing "ongoing progress...in internal and collaborative R&D projects"

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next